Takeda Says Japan Approves CUVITRU Subcutaneous Immunoglobulin For Patients With Agammaglobulinemia

RTTNews | 652 days ago
Takeda Says Japan Approves CUVITRU Subcutaneous Immunoglobulin For Patients With Agammaglobulinemia

(RTTNews) - Takeda Pharmaceutical Co. Ltd. (TAK) announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] in patients aged 2 years and older with agammaglobulinemia or hypogammaglobulinemia disorders.

This is characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency (PID) or secondary immunodeficiency (SID).

The approval marks Takeda's first subcutaneous immunoglobulin (SCIG) therapy for patients in Japan.

The approval is based on results from a Phase 3 clinical trial that evaluated the efficacy, safety, tolerability and pharmacokinetics of CUVITRU in Japanese patients with PID, as well as two Phase 2/3 clinical trials conducted in patients with PID in North America and Europe.

Results from the clinical trial in 17 patients in Japan confirmed its efficacy and safety profile and CUVITRU was well-tolerated. Previously reported clinical trial results also confirmed the efficacy and safety of CUVITRU.

read more
Takeda Says FDA Approves EOHILIA To Treat Eosinophilic Esophagitis

Takeda Says FDA Approves EOHILIA To Treat Eosinophilic Esophagitis

Japan's Takeda Pharmaceutical Co. Ltd. (TAK) announced Monday that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE)1 It will be available in 2 mg/10 mL convenient, single-dose stick packs by the end of February.
RTTNews | 512 days ago
Takeda Canada Inks Contract With Canadian Blood Services For GLASSIA

Takeda Canada Inks Contract With Canadian Blood Services For GLASSIA

Takeda Canada Inc., the Canadian arm of Japan's Takeda Pharmaceutical Co. Ltd. (TAK) on Wednesday entered into a contract with Canadian Blood Services (CBS) for GLASSIA (alpha-1 proteinase inhibitor) resulting from CBS's request for proposal for hereditary deficiency of Alpha-1 Antitrypsin Deficiency (Alpha-1).
RTTNews | 566 days ago
Takeda Says FDA Accepts BLA For ENTYVIO For Maintenance Therapy In Crohn's Disease

Takeda Says FDA Accepts BLA For ENTYVIO For Maintenance Therapy In Crohn's Disease

Takeda Pharmaceutical Co. Ltd. (TAK) announced Wednesday that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the investigational subcutaneous (SC) administration of ENTYVIO (vedolizumab) for maintenance therapy in adults with moderately to severely active Crohn's disease (CD) after induction therapy with ENTYVIO intravenous (IV).
RTTNews | 664 days ago
Sensex, Nifty Tad Lower Dragged By IT Stocks

Sensex, Nifty Tad Lower Dragged By IT Stocks

Indian shares opened a tad lower on Wednesday after U.S. President Donald Trump offered no exceptions to his Aug. 1 tariff start date and announced a 50 percent tariff on copper imports, expanding trade measures already in place for steel and aluminum.
RTTNews | 14 minutes ago
Australian Market More Than Halves Early Losses In Mid-market

Australian Market More Than Halves Early Losses In Mid-market

The Australian stock market is halving its early losses in mid-market moves on Wednesday, reversing the slight gains in the previous session, with the benchmark S&P/ASX 200 staying below the 8,600 level, following the mixed cues from Wall Street overnight, with weakness in financial and technology stocks partially offset by gains in mining and energy stocks.
RTTNews | 1h 11min ago
Asian Markets Mixed Amid Tariff Worries

Asian Markets Mixed Amid Tariff Worries

Asian stock markets are trading mixed on Wednesday, following the mixed cues from Wall Street overnight, as traders are reluctant to make significant moves amid the lingering uncertainty about US trade policy after US President Donald Trump delayed the reciprocal tariff deadline until August 1. Asian markets closed mostly higher on Tuesday.
RTTNews | 1h 37min ago